Self-efficacy and motivation to quit during participation in a smoking cessation program.
The associations between failure to quit and posttreatment self-efficacy and motivation were examined among 600 African American smokers enrolled in a randomized trial testing the efficacy of bupropion for smoking cessation. Participants also received brief motivational counseling and were followed for 6 months. Baseline levels of self-efficacy and motivation for all participants were high (8.2 and 8.5 on a 10-point scale, respectively). Longitudinal analyses indicated that smokers who failed to quit were less likely than quitters to report high self-efficacy and motivation from posttreatment to follow-up. However, examination of mean self-efficacy and motivation scores at posttreatment and follow-up revealed that smokers continued to sustain high self-efficacy and motivation. Mean self-efficacy and motivation scores differed by less than 1 point from baseline levels, even though the majority of participants failed to quit smoking. Results suggest that unsuccessful participation in a smoking cessation program does not meaningfully reduce smokers' self-efficacy and motivation to quit.
Boardman
Thuy
T
Department of Preventive Medicine and Public Health, University of Kansas Medical Center, Kansas City, KS, USA.
Catley
Delwyn
D
Mayo
Matthew S
MS
Ahluwalia
Jasjit S
JS
D000328:Adult; D001741:Black or African American / Q000523:psychology; D016642:Bupropion / Q000627:therapeutic use; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009042:Motivation; D010919:Placebos; D020377:Self Efficacy; D016540:Smoking Cessation / Q000523:psychology*; D014029:Tobacco Use Disorder / Q000188:drug therapy / Q000523:psychology; D016896:Treatment Outcome
D018765:Dopamine Uptake Inhibitors; D010919:Placebos; D016642:Bupropion